New Delhi: As India started vaccinating its teenagers, Bharat Biotech, the maker of Covaxin, has started to pick up unused stock from private hospitals to re-label the shelf life. Covaxin is the only vaccine available for vaccination drive for teenagers now. The company got a shelf life extension in December, when the country’s drug regulator…
1,48,184 beneficiaries in Mysuru; official launch at 8.30 am Registration begins on CoWin portal; 2 lakh doses in stock Mysore/Mysuru: On Monday, Jan. 3, the State Government will kick off the Covaxin drive for the 15-18 years age group in schools and PU colleges, with the Centre announcing vaccination for teens. While Karnataka has to…
1.47 lakh beneficiaries in Mysuru district Plans afoot to open vaccination centres Over 400 booths needed in entire district Mysore/Mysuru: With the vaccination of those aged between 15 years and 18 years set to begin from Monday, Jan. 3, 2022, Deputy Commissioner (DC) Dr. Bagadi Gautham reviewed the preparations with District Health Officer (DHO) Dr….
Covaxin has shown good immune response in children in clinical trials New Delhi: Children in the age group of 15-18 years will be able to register on the CoWIN app from Jan. 1, 2022, two days before the vaccination programme is expanded across the country to include them. “We have added an additional (10th) ID…
Mysore/Mysuru: Bharat Biotech last week celebrated Covaxin’s Emergency Use Listing (EUL) by the World Health Organisation (WHO), two days after the global health organisation gave the much-anticipated nod to India’s indigenous vaccine. While celebrating the go-ahead given to the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech in partnership with ICMR and the National Institute of…
Covaxin gets emergency approval for kids aged 2-18 years by Subject Expert Committee New Delhi: In a major gain, India’s indigenous COVID vaccine — Covaxin — has been approved for children aged 2-18 years by the Subject Expert Committee (SEC) this noon. Covaxin has overall efficacy of 77.8 percent against COVID and 65.2 percent protection…
Mysore/Mysuru: The first round of Covaxin vaccine trial on children in several age groups has been successfully completed at Cheluvamba Hospital in city. “There has been no side effects on any child and all of them are safe and healthy after taking the first dose of vaccine,” said Dr. C.P. Nanjaraj, Dean and Director, Mysore…
Mysore/Mysuru: Children aged between 12 and 18 years, who were administered Covaxin doses at Mysore Medical College and Research Institute (MMC&RI) as part of the clinical trial, are healthy, fit and fine, officials said here on Sunday. As many as 30 children were administered the vaccine at Cheluvamba Hospital, a constituent hospital of MMC&RI. The…
30 kids get trial jabs at Cheluvamba; No vaccine adverse effects observed Mysore/Mysuru: Hyderabad-based pharmaceutical major Bharat Biotech has begun the clinical trials of its COVID-19 vaccine, Covaxin, on children aged 12-18 years in several parts of the country including Mysuru where children volunteers have started receiving their shots. In Mysuru, the trials are being…
One among 10 Hospitals selected for trials in India; Dedicated team formed Mysore/Mysuru: Amid a debate around inoculating children for the deadly COVID infection and the threat of the third wave where teens and children are predicted to be the worst affected, Cheluvamba Hospital in Mysuru has been selected by Institutional Ethics Committee for Covaxin’s…
April 25, 2024
Come, let us march to the polling booths tomo...April 25, 2024
Captivating Veena ConcertApril 25, 2024
Dangerous condition of dry tree on SJCE RoadApril 25, 2024
Recent Comments